P3 Health Partners (PIII) Earnings Date & Reports

Key Takeaways

• P3 Health Partners reported third quarter 2026 total revenue of $396.3 million, up 15% year over year, beating the consensus estimate of roughly $385 million.
• The company swung to net income of $30.8 million, compared with a net loss of $69.5 million in the prior-year quarter.
• Diluted earnings per share (EPS) reached $0.07, a sharp improvement from a loss of $9.67 per share a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $20.9 million, versus a $45.9 million loss a year ago, and management raised the midpoint of its full-year 2026 Adjusted EBITDA guidance to $100 million.
• At-risk membership declined 9% year over year to approximately 105,000 members, reflecting the company's deliberate network and payer rationalization strategy.
• Get more details on P3 Health Partners' Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to see how AI-driven tools are identifying market opportunities.

Earnings Context and Why It Matters

P3 Health Partners is a patient-centered, physician-led population health management company that supports primary care providers with value-based care coordination and administrative services. After years of losses, the company has been executing a deliberate turnaround centered on rationalizing its provider network and improving the economics of its capitated Medicare Advantage contracts. This quarter matters because it offers the clearest sign yet that the turnaround is translating into sustained profitability. With Adjusted EBITDA turning positive for a third consecutive quarter and management lifting its full-year guidance midpoint, investors are watching closely to see whether P3 can carry its improved medical cost trends and operating discipline into 2027.

Reported Results

For the third quarter ended September 30, 2026, P3 Health Partners reported total operating revenue of $396.3 million, an increase of 15% compared with $345.3 million in the prior-year quarter and above the consensus estimate of about $385 million. Capitated revenue rose to $366.3 million, while other revenue climbed to $30.1 million from $3.7 million a year earlier.

The company posted net income of $30.8 million, a dramatic reversal from the $69.5 million net loss reported in the same period last year. Diluted EPS came in at $0.07, compared with a loss of $9.67 per share a year ago. Net income attributable to Class A common stockholders was $451,000, or $0.13 basic EPS, after cumulative preferred stock dividends of $15.2 million.

On an operating basis, Adjusted EBITDA reached $20.9 million, or $66 per member per month (PMPM), versus a loss of $45.9 million a year earlier. Medical margin for the quarter was $43.9 million, or $140 PMPM, though this figure benefited from favorable payer settlements and prior-year development. Excluding those items, medical margin was $35.0 million, or $111 PMPM. At-risk membership was approximately 105,000, down 9% year over year, while total lives under management stood at roughly 133,500.

Management revised its full-year 2026 Adjusted EBITDA guidance to a range of $90 million to $110 million, raising the midpoint to $100 million. Full-year revenue guidance was maintained at $1.525 billion to $1.600 billion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, the screener helps investors focus their research on the names that matter most to their strategy. Consider exploring the AI Screener to complement your own analysis of stocks like PIII.

Market Reaction and Investor Sentiment

Shares of P3 Health Partners moved higher following the release, as investors responded to the company's larger-than-expected profit swing and the upward revision to its Adjusted EBITDA guidance. The market's initial read focused on the durability of the earnings improvement, with management emphasizing year-to-date Adjusted EBITDA of $101 million and a normalized Medicare Advantage medical expense trend that remains below prior-year levels.

At the same time, sentiment was tempered by signs that the quarter's headline results carried meaningful one-time support. Roughly $12 million of the $21 million in Adjusted EBITDA came from items such as a favorable 2025 CMS ACO reconciliation and a non-cash liability release, while the adjusted medical loss ratio rose sequentially to about 90.6%. Investors are weighing the strength of the underlying business against these non-recurring contributions.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be focused on whether P3 Health Partners can sustain its profitability into 2027. Management has identified more than $200 million of potential multi-year value creation across payer economics, clinical execution, and operating efficiency, and has said it will provide greater clarity on the timing and earnings contribution of these opportunities early in 2027.

The trajectory of medical costs will be a central watch item. Although Medicare Advantage medical expense remains favorable versus prior-year levels on a normalized basis, the third quarter showed a sequential uptick in the medical loss ratio, driven in part by outpatient and professional services utilization. Sustaining cost discipline will be essential to protecting margins.

Other factors to monitor include the ramp of the Nebraska build-out, progress in growing per-member capitated revenue, and the company's pipeline of Medicare Advantage plan opportunities. Membership trends will also matter: the intentional reduction in at-risk lives has improved economics, but investors will want to see the base stabilize and begin to grow again. The recent appointment of a new Chief Clinical Officer adds another layer to watch as P3 deepens its clinical execution ahead of 2027 guidance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations